NO20062661L - Beta-laktamer for behandling av CNS lidelser - Google Patents

Beta-laktamer for behandling av CNS lidelser

Info

Publication number
NO20062661L
NO20062661L NO20062661A NO20062661A NO20062661L NO 20062661 L NO20062661 L NO 20062661L NO 20062661 A NO20062661 A NO 20062661A NO 20062661 A NO20062661 A NO 20062661A NO 20062661 L NO20062661 L NO 20062661L
Authority
NO
Norway
Prior art keywords
cyano
hydroxy
halogen
alkyl
represents hydrogen
Prior art date
Application number
NO20062661A
Other languages
English (en)
Inventor
Romano Di Fabio
Giuseppe Alvaro
Riccardo Giovannini
Maria Elvira Tranquillini
Alfredo Paio
Lucia Mattio
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20062661L publication Critical patent/NO20062661L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår nye forbindelser med formel (I), hvori — representerer en enkel- eller dobbelbinding; R representerer et radikal valgt fra formlene i), ii), iii) og iv) hvori Rer halogen, cyano, C_alkyl, Calkoksy, trifluormetyl eller trifluormetoksy og p er null eller et heltall på fra 1 til 3; Rrepresenterer hydrogen eller C_alky 1; Rrepresenterer hydrogen, hydroksy eller C_alkyl; Rrepresenterer hydrogen eller Rsammen med Rrepresenterer =0 eller =CH; Rrepresenterer fenyl, naftyl, en 9- til 10-leddet, sammensmeltet, bicyklisk heterocyklisk gruppe eller en 5- eller 6-leddet heteroarylgnippe, hvori nevnte grupper eventuelt er substituert med 1 til 3 grupper uavhengig valgt fra trifluormetyl, Calkyl, hydroksy, cyano, Calkoksy, trifluormetoksy, halogen eller S(0)qCalkyl; Rog Rrepresenterer uavhengig hydrogen, cyano, Calkyl; Rg er (CH)R; Rrepresenterer hydrogen, halogen, C.cykloalkyl, hydroksy, nitro, cyano eller C_alkyl eventuelt substituert med en eller to grupper valgt fra halogen, cyano, hydroksy eller C_alkoksy; Rio representerer hydrogen eller C_cykloalkyl; n representerer 1 eller 2; q er 0, 1 eller 2; r er 0 eller et heltall fra 1 til 4; eller et farmasøytisk akseptabelt salt eller solvat derav, fremgangsmåter for deres fremstilling og deres anvendelse ved behandling av tilstander mediert av takykininer og/eller ved selektiv inhibering av serotoningjenopptakningstransporterproteinet.
NO20062661A 2003-11-12 2006-06-09 Beta-laktamer for behandling av CNS lidelser NO20062661L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326407.4A GB0326407D0 (en) 2003-11-12 2003-11-12 Chemical compounds
PCT/EP2004/012772 WO2005049600A1 (en) 2003-11-12 2004-11-10 Beta-lactams for treatment of cns disorders

Publications (1)

Publication Number Publication Date
NO20062661L true NO20062661L (no) 2006-06-09

Family

ID=29726427

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062661A NO20062661L (no) 2003-11-12 2006-06-09 Beta-laktamer for behandling av CNS lidelser

Country Status (28)

Country Link
US (1) US20080262041A1 (no)
EP (1) EP1689737B1 (no)
JP (1) JP2007510692A (no)
KR (1) KR20060118477A (no)
CN (1) CN1878764A (no)
AR (1) AR046233A1 (no)
AT (1) ATE401321T1 (no)
AU (1) AU2004291296B2 (no)
BR (1) BRPI0416285A (no)
CA (1) CA2546007A1 (no)
CY (1) CY1108404T1 (no)
DE (1) DE602004015144D1 (no)
DK (1) DK1689737T3 (no)
ES (1) ES2310295T3 (no)
GB (1) GB0326407D0 (no)
HK (1) HK1094698A1 (no)
HR (1) HRP20080501T3 (no)
IL (1) IL175279A0 (no)
IS (1) IS8477A (no)
MA (1) MA28156A1 (no)
MY (1) MY138378A (no)
NO (1) NO20062661L (no)
PL (1) PL1689737T3 (no)
PT (1) PT1689737E (no)
RU (1) RU2006120417A (no)
SI (1) SI1689737T1 (no)
TW (1) TW200528439A (no)
WO (1) WO2005049600A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085042A1 (en) 2006-01-24 2007-08-02 Biosignal Limited Novel lactams
AU2015200142B2 (en) * 2006-01-24 2016-07-07 Unilever Plc Novel lactams

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130088C (no) * 1960-03-14
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2083891A1 (en) * 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
GB9200535D0 (en) * 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
US5824690A (en) * 1993-05-06 1998-10-20 Hoechst Marion Roussel Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
ATE177095T1 (de) * 1994-08-25 1999-03-15 Merrell Pharma Inc Substituierte piperidine für die behandlung von allergischen krankheiten
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
FR2779429B1 (fr) * 1998-06-03 2000-07-13 Synthelabo Derives d'oxindole, leurs preparations et leurs applications en therapeutique
US6204265B1 (en) * 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
GB0114867D0 (en) * 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
BRPI0416285A (pt) 2007-01-23
WO2005049600A1 (en) 2005-06-02
SI1689737T1 (sl) 2008-12-31
MY138378A (en) 2009-05-29
HRP20080501T3 (en) 2008-11-30
HK1094698A1 (en) 2007-04-04
EP1689737A1 (en) 2006-08-16
CA2546007A1 (en) 2005-06-02
IL175279A0 (en) 2006-09-05
AU2004291296B2 (en) 2011-04-07
US20080262041A1 (en) 2008-10-23
ES2310295T3 (es) 2009-01-01
MA28156A1 (fr) 2006-09-01
TW200528439A (en) 2005-09-01
CN1878764A (zh) 2006-12-13
ATE401321T1 (de) 2008-08-15
AR046233A1 (es) 2005-11-30
GB0326407D0 (en) 2003-12-17
DE602004015144D1 (de) 2008-08-28
AU2004291296A1 (en) 2005-06-02
PT1689737E (pt) 2008-10-24
KR20060118477A (ko) 2006-11-23
IS8477A (is) 2006-05-22
CY1108404T1 (el) 2014-02-12
EP1689737B1 (en) 2008-07-16
PL1689737T3 (pl) 2008-12-31
RU2006120417A (ru) 2007-12-27
DK1689737T3 (da) 2008-10-27
JP2007510692A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
AU2011297889B2 (en) Pharmaceutically active compounds as Axl inhibitors
KR101645379B1 (ko) 선택적 히스톤 탈아세틸화 효소 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
WO2016071293A2 (en) Pharmaceutical compound
NO20051051L (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler
PE20231312A1 (es) Derivados triciclicos de carboxamida como inhibidores de la prmt5
JP3981406B2 (ja) ５−ｈｔ４レセプター拮抗薬
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20071140L (no) Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
EA200401431A1 (ru) Производные триазола в качестве антагонистов рецептора тахикинина
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
JP6458028B2 (ja) インドール及びピロールの新規な誘導体、その製造方法及びそれを含む医薬組成物
BRPI0409110A (pt) derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
CN101679255A (zh) 用于炎症治疗的哌啶酮类
ATE480239T1 (de) Angiogeneseinhibitoren
AR087354A1 (es) Inhibidores selectivos de la proteina quinasa
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
RU2006109004A (ru) 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны
JP2004523475A (ja) タンパク質Ｊｕｎキナーゼのインヒビターとしての医薬的活性ベンズスルホンアミド誘導体
DK2139881T3 (da) Quinoliner og deres terapeutiske anvendelse
JP2008525398A5 (no)
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
AR071619A1 (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen.
NO20062661L (no) Beta-laktamer for behandling av CNS lidelser
RU2011102472A (ru) Замещенные 7-сульфанилметил-, 7-сульфинилметил- и 7-сульфонилметил-индолы и их применение
EA201070532A1 (ru) Новые непептидные производные соединения в качестве b1 антагонистов брадикинина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application